Haemonetics (HAE) EV to EBITDA (2009 - 2026)

Haemonetics has reported EV to EBITDA for 18 years, with the latest figure at 57.28 in Q2 2026.

• On a quarterly basis, EV to EBITDA fell 5.38% year-over-year to 57.28 in Q2 2026; TTM through Jun 2026 was 20.53, a 48.51% increase from a year earlier, with the FY2026 full-year figure at 14.04, up 13.63% from the prior year.
• EV to EBITDA was 57.28 for Q2 2026 at Haemonetics, up from 95.55 in the prior quarter.
• The five-year high for EV to EBITDA was 156.51 in Q2 2022, with the low at 95.55 in Q1 2026.
• Average EV to EBITDA over 5 years is 73.73, with a median of 75.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: EV to EBITDA jumped 160.18% in 2022, then plunged 348.76% in 2026.
• Over 5 years, EV to EBITDA stood at 86.5 in 2022, then rose by 4.32% to 90.23 in 2023, then slumped by 32.86% to 60.58 in 2024, then fell by 16.82% to 50.39 in 2025, then increased by 13.67% to 57.28 in 2026.
• The last three EV to EBITDA figures came in at 57.28 (Q2 2026), 95.55 (Q1 2026), and 50.39 (Q4 2025), per Business Quant data.